Daratumumab is the first in-class monoclonal anti-CD38 immunoglobulin G1 antibody with proven antimyeloma activity in both monotherapy and in combination with drugs such as lenalidomide and bortezomib.1 It has a favorable safety profile with typical adverse events such as upper respiratory tract symptoms at first infusion and later immunosuppressive effects.2